2026-10-14T14:38:00Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33992008 2026-09-25T04:25:18Z category_363 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_Tenecteplase versus alteplase for intravenous thrombolysis in acute ischemic stroke: a single-center propensity-weighted cohort study.docx Jin Ma (335456) Heyireguli Wulayimu (25107010) Zhiqiang Ma (127376) Neurology and Neuromuscular Diseases acute ischemic stroke alteplase functional outcome intravenous thrombolysis inverse probability of treatment weighting tenecteplase Background<p>Tenecteplase can be given as a single bolus, but comparative estimates from routine stroke care are susceptible to treatment-selection bias. Methods: We reviewed 269 adults treated at one center with intravenous tenecteplase (n = 110) or alteplase (n = 159) within 4.5 h of symptom onset from March 2024 through March 2026. The primary outcome was functional independence at 90 days [modified Rankin Scale (mRS) 0–2]. A logistic propensity-score model included pretreatment clinical and laboratory variables. Stabilized average-treatment-effect weights were truncated at the 1st and 99th percentiles. We report weighted risks, risk differences (RDs), odds ratios (ORs), and robust 95% confidence intervals (CIs). Secondary neurological/workflow and safety outcomes were adjusted within separate families using the Holm procedure.</p>Results<p>After weighting, 90-day functional independence was 77.9% with tenecteplase and 81.3% with alteplase (RD, −3.5 percentage points; 95% CI, −17.0 to 10.1; p = 0.616; OR, 0.81; 95% CI, 0.36–1.82). Holm-adjusted p values for the other functional outcomes were 1.000. The weighted mean difference in door-to-needle time was −5.0 min (95% CI, −9.0 to −0.9; unadjusted p = 0.017; Holm-adjusted p = 0.068). Day-7 early neurological deterioration occurred in no tenecteplase recipient and nine alteplase recipients (weighted RD, −5.1 percentage points; 95% CI, −8.5 to −1.7; Holm-adjusted p = 0.016). SITS-MOST symptomatic intracranial hemorrhage occurred in four patients, with a weighted RD of 0.2 percentage points (95% CI, −1.7 to 2.1).</p>Conclusion<p>Tenecteplase was not associated with greater 90-day functional independence in this propensity-weighted cohort. No clear between-group difference was observed in major hemorrhagic outcomes. DNT was shorter before multiplicity adjustment, and day-7 deterioration was less frequent after adjustment within the secondary neurological/workflow family.</p> 2026-09-25T04:25:18Z Dataset Dataset 10.3389/fneur.2026.1928004.s001 https://figshare.com/articles/dataset/Supplementary_file_1_Tenecteplase_versus_alteplase_for_intravenous_thrombolysis_in_acute_ischemic_stroke_a_single-center_propensity-weighted_cohort_study_docx/33992008 CC BY 4.0